HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine

An important goal of human immunodeficiency virus (HIV) vaccine design is identification of strategies that elicit effective antiviral humoral immunity. One novel approach comprises priming with DNA and boosting with modified vaccinia virus Ankara (MVA) expressing HIV-1 Env on virus-like particles....

詳細記述

保存先:
書誌詳細
出版年:J Virol
主要な著者: Shen, Xiaoying, Basu, Rahul, Sawant, Sheetal, Beaumont, David, Kwa, Sue Fen, LaBranche, Celia, Seaton, Kelly E., Yates, Nicole L., Montefiori, David C., Ferrari, Guido, Wyatt, Linda S., Moss, Bernard, Alam, S. Munir, Haynes, Barton F., Tomaras, Georgia D., Robinson, Harriet L.
フォーマット: Artigo
言語:Inglês
出版事項: American Society for Microbiology 2017
主題:
Vaccines and Antiviral Agents
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5709589/
https://ncbi.nlm.nih.gov/pubmed/29021394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01077-17
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料